Sun Pharma gets FDA approval for diabetes generic drug
REUTERS - Sun Pharmaceutical Industries(SUN.NS) said on Friday it has received final approval from the United States Food and Drug Administration (FDA) to launch the generic version of Novo Nordisk's (NOVOb.CO) Prandin diabetes drug.
Prandin, known chemically as repaglinide, and its combination with the commonly prescribed type 2 diabetes drug metformin, sold as PrandiMet, had sales of about $200 million in 2012 for Novo.
Sun Pharma said it would be eligible for a 180-day marketing exclusivity in the United States for the drug.
A U.S. appeals court last month found the patent on Novo's Prandin diabetes drug in combination with metformin to be invalid, paving the way for the introduction of a generic version of the drug.
(Reporting by Sumeet Chatterjee in MUMBAI; Editing by Supriya Kurane)
- Tweet this
- Share this
- Digg this
- UPDATE 2-U.S. House passes bill to avert govt shutdown, extend Export-Import bank
- IPhone emerges from "bygone era", reviewers hail bigger handset
- UPDATE 1-Apple to unveil new iPads, operating system on Oct. 21 - report
- Fed renews zero rate pledge, but hints at steeper rate hike path
- UPDATE 2-Bug delays Apple's HealthKit availability on iOS 8
The United States said on Wednesday it will press Prime Minister Narendra Modi to end his blockage of a global trade pact when he visits Washington this month, something that could dampen the mood of a trip aimed at revitalizing strategic ties. Full Article
China cenbank injects $81 bln into major banks to support economy - reports Full Article